One of the key aspects of the article is the discussion of CRISPR technology. Khasanov emphasizes that this is not just a tool for editing genes, but also a powerful driver of profit for companies. He gives examples of giants such as Vertex Pharmaceuticals and CRISPR Therapeutics, which are actively using this technology to treat various diseases, including beta thalassemia and HIV. However, the author notes that the cost of such treatments can reach $2-3 million per patient, which makes them inaccessible to everyone and brings significant benefits to investors.

Khasanov also draws attention to CAR-T therapy, an innovative approach to cancer treatment that sounds like a plot from Star Trek. The essence of this technology is to reprogram the patient's immune cells to fight cancer cells. Novartis' Kymriah and Gilead's Yescarta have already become real blockbusters on the market. However, the production of these drugs costs more than $ 500,000 per dose, which highlights the high cost of innovative biotechnology.

In the conclusion of his article, Khasanov invites readers to think about whether it is worth betting on biology as a business of the future. He hints that investing in this area can be extremely profitable, but requires careful analysis and understanding of all the risks.

For those interested in an in-depth study of the topic and receiving additional advice on investing in biotechnology, the author suggests following the link in his article. Thus, Khasanov creates a holistic view of the current state of biotechnology and its potential as a business of the future.